Komo Biosciences
5 known investors
Find your way into Komo Biosciences
510 people in our graph share verified history with the Komo Biosciences team — schools, employers, funds. One of them is your warm intro.
Satish Dharmarajunlockedknows Jennifer Manning · together at Clemson University
×6knows the team · via University of California, Santa Cruz
×3knows the team · via Harvard T.H. Chan School of Public Health
×2knows the team · via Clemson University
KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.
Founders & leadership
JM
Jennifer ManninginFounder & CEOJennifer Manning founded KOMO Biosciences, a genome engineering company developing serine integrase-mediated platforms for large-payload genome insertion, and has over 30 years of experience in biotechnology commercialization, business development, and executive leadership across life sciences and biopharmaceutical sectors. She currently serves as a Strategic Advisor and Board Member at KOMO and is Founder and Managing Partner of Starlight Advisory Group, an executive advisory firm serving biotechnology and life sciences companies.
TP
Thomas PageinActing CTO
MF
Matt FarabaughActing CFO
JB
Jesse B. OwensinActing CSAJesse B. Owens is a genome engineering researcher who has focused on improving targeted gene delivery since publishing work on transposase-based genomic targeting in 2012. He founded Komo Biosciences to develop integrase-based technologies for cell-based manufacturing of biologics and advanced therapies, drawing on his expertise in protein engineering and directed evolution methods including phage-assisted continuous evolution.
Board
RT
Investors · 5
Competitors · 3
by search overlap
Precision BioSciences5 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
IQVIA4 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Curi Bio3 shared keywordsCuri Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.
Companies competing with Komo Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Komo Biosciences do?
- KOMO Biosciences develops genome engineering technology based on hyperactive large serine integrases to transform cell-based manufacturing of biologics and advanced therapies. The company was founded around record-breaking integrase technology for improving gene editing vectors.
- Who founded Komo Biosciences?
- Komo Biosciences was founded by Jennifer Manning.
- Who are Komo Biosciences's investors?
- Komo Biosciences's investors include Genesis BioCapital, Eshelman Ventures, LLC, Modi Ventures, GENERAL INCEPTION, LDV Partners.